HomeCompareMRES vs ARCC

MRES vs ARCC: Dividend Comparison 2026

MRES yields 142857.14% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRES wins by $1.703105290929614e+28M in total portfolio value
10 years
MRES
MRES
● Live price
142857.14%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.703105290929614e+28M
Annual income
$17,007,633,297,048,937,000,000,000,000,000,000.00
Full MRES calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — MRES vs ARCC

📍 MRES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRESARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRES + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MRES pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRES
Annual income on $10K today (after 15% tax)
$12,142,857.14/yr
After 10yr DRIP, annual income (after tax)
$14,456,488,302,491,595,000,000,000,000,000,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, MRES beats the other by $14,456,488,302,491,595,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRES + ARCC for your $10,000?

MRES: 50%ARCC: 50%
100% ARCC50/50100% MRES
Portfolio after 10yr
$8.51552645464807e+27M
Annual income
$8,503,816,648,524,468,000,000,000,000,000,000.00/yr
Blended yield
99.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

MRES
No analyst data
Altman Z
-24.2
Piotroski
1/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRES buys
0
ARCC buys
0
No recent congressional trades found for MRES or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRESARCC
Forward yield142857.14%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$1.703105290929614e+28M$24.5K
Annual income after 10y$17,007,633,297,048,937,000,000,000,000,000,000.00$1.16
Total dividends collected$1.70295189426983e+28M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: MRES vs ARCC ($10,000, DRIP)

YearMRES PortfolioMRES Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$14,296,414$14,285,714.29$11,381$541.15+$14.29MMRES
2$19,102,632,658$19,087,335,494.95$12,621$284.08+$19102.62MMRES
3$23,856,124,353,624$23,835,684,536,679.88$13,827$145.31+$23856124.34MMRES
4$27,845,102,711,212,050$27,819,576,658,153,670.00$15,062$73.43+$27845102711.20MMRES
5$30,376,787,884,694,190,000$30,346,993,624,793,194,000.00$16,364$36.89+$30376787884694.17MMRES
6$30,972,831,647,170,750,000,000$30,940,328,484,134,132,000,000.00$17,757$18.49+$30972831647170752.00MMRES
7$29,516,720,240,819,920,000,000,000$29,483,579,310,957,454,000,000,000.00$19,258$9.25+$29516720240819920896.00MMRES
8$26,290,911,335,300,946,000,000,000,000$26,259,328,444,643,270,000,000,000,000.00$20,880$4.63+$2.6290911335300947e+22MMRES
9$21,887,488,081,496,375,000,000,000,000,000$21,859,356,806,367,600,000,000,000,000,000.00$22,636$2.32+$2.1887488081496375e+25MMRES
10$17,031,052,909,296,140,000,000,000,000,000,000$17,007,633,297,048,937,000,000,000,000,000,000.00$24,539$1.16+$1.703105290929614e+28MMRES

MRES vs ARCC: Complete Analysis 2026

MRESStock

Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Its services include regulatory control of industrial activities and products; scientific surveillance of the living environment; research and development of biomedical products and technologies; regulatory evaluation and certification of biomedical products; fundamental scientific research; and development of new diagnostic methods and experimental medical treatments. The company also researchers and develops new biomedical and food products; provides programs for graduate research studies in biomedical and environmental fields; offers two channel analog NMS, digital muscle stimulator, digital TENS, interferential, elite combination, portable four channel digital, portable ultra sound, and other healthcare devices; and provides photon red light for beauty, electric pain relief products, microcurrent electrical nerve stimulators, and high volt pulsed stimulators. In addition, it develops and commercializes microbicidal agents; disinfectant products; bandages for large burns, hard surface disinfection, microbicidal treatment of fabrics and textile products, insecticides against bed bugs and other textile goods, microbicidal towels, and mouthwash products; Purilair, an appliance that sterilizes compressed air circulating within medical instruments; colloidal silver and electro medical devices; and BioStim INF that is used for edema reduction, pain relief, and total treatment. Further, the company provides quality control, regulatory, healthcare, environmental services, environmental analysis, building decontamination, and environmental protection and management services; and regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was founded in 2010 and is based in Podgorica, Montenegro with a representative office in Montreal, Canada.

Full MRES Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this MRES vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRES vs SCHDMRES vs JEPIMRES vs OMRES vs KOMRES vs MAINMRES vs HTGCMRES vs GBDCMRES vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.